Advances in antibody-based therapy in oncology

doi:10.1038/s43018-023-00516-z

Review

. 2023 Feb;4(2):165-180.

doi: 10.1038/s43018-023-00516-z. Epub 2023 Feb 20.

Advances in antibody-based therapy in oncology

Sacha Zinn^{1

2}, Rodrigo Vazquez-Lombardi^{1

2

3}, Carsten Zimmermann^{4

5}, Puja Sapra⁶, Lutz Jermutus⁷, Daniel Christ^{8

9}

Affiliations

¹ Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
² Faculty of Medicine, The University of New South Wales, St Vincent's Clinical School, Darlinghurst, Sydney, New South Wales, Australia.
³ Engimmune Therapeutics, Allschwil, Switzerland.
⁴ University of San Diego, Knauss School of Business, San Diego, CA, USA.
⁵ University of California San Diego, La Jolla, CA, USA.
⁶ AstraZeneca, Oncology R&D, Biologics Engineering & Targeted Delivery, Gaithersburg, MD, USA.
⁷ AstraZeneca, BioPharmaceuticals R&D, Research & Early Development, Cambridge, UK.
⁸ Garvan Institute of Medical Research, Sydney, New South Wales, Australia. d.christ@garvan.org.au.
⁹ Faculty of Medicine, The University of New South Wales, St Vincent's Clinical School, Darlinghurst, Sydney, New South Wales, Australia. d.christ@garvan.org.au.

PMID: 36806801
DOI: 10.1038/s43018-023-00516-z

Review

Advances in antibody-based therapy in oncology

Sacha Zinn et al. Nat Cancer. 2023 Feb.

. 2023 Feb;4(2):165-180.

doi: 10.1038/s43018-023-00516-z. Epub 2023 Feb 20.

Authors

Sacha Zinn^{1

2}, Rodrigo Vazquez-Lombardi^{1

2

3}, Carsten Zimmermann^{4

5}, Puja Sapra⁶, Lutz Jermutus⁷, Daniel Christ^{8

9}

Affiliations

¹ Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
² Faculty of Medicine, The University of New South Wales, St Vincent's Clinical School, Darlinghurst, Sydney, New South Wales, Australia.
³ Engimmune Therapeutics, Allschwil, Switzerland.
⁴ University of San Diego, Knauss School of Business, San Diego, CA, USA.
⁵ University of California San Diego, La Jolla, CA, USA.
⁶ AstraZeneca, Oncology R&D, Biologics Engineering & Targeted Delivery, Gaithersburg, MD, USA.
⁷ AstraZeneca, BioPharmaceuticals R&D, Research & Early Development, Cambridge, UK.
⁸ Garvan Institute of Medical Research, Sydney, New South Wales, Australia. d.christ@garvan.org.au.
⁹ Faculty of Medicine, The University of New South Wales, St Vincent's Clinical School, Darlinghurst, Sydney, New South Wales, Australia. d.christ@garvan.org.au.

PMID: 36806801
DOI: 10.1038/s43018-023-00516-z

Abstract

Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances in the field with a particular focus on recent and emerging classes of engineered antibody therapeutic candidates, discuss molecular structure and mechanisms of action and provide updates on clinical development and practice.

PubMed Disclaimer

Cited by

Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy.
Wang X, Zhang H, XinZhang, Liu Y. Wang X, et al. Biomark Res. 2024 Sep 4;12(1):98. doi: 10.1186/s40364-024-00628-3. Biomark Res. 2024. PMID: 39228005 Free PMC article. Review.
Treatment patterns and factors associated with discontinuation of monoclonal antibodies.
Alkaabi MMS, Rabbani SA, Rao PG, Mohamedelhassan MI. Alkaabi MMS, et al. SAGE Open Med. 2024 Aug 19;12:20503121241271817. doi: 10.1177/20503121241271817. eCollection 2024. SAGE Open Med. 2024. PMID: 39165864 Free PMC article.
Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.
Sanvicente García A, Pedregal M, Paniagua-Herranz L, Díaz-Tejeiro C, Nieto-Jiménez C, Pérez Segura P, Munkácsy G, Győrffy B, Calvo E, Moreno V, Ocaña A. Sanvicente García A, et al. Int J Mol Sci. 2024 May 14;25(10):5345. doi: 10.3390/ijms25105345. Int J Mol Sci. 2024. PMID: 38791382 Free PMC article.
Understanding the Preclinical Efficacy of Antibody-Drug Conjugates.
Díaz-Tejeiro C, López de Sá A, Poyatos-Racionero E, Ballestín P, Bartolomé J, Calvo E, Moreno V, Moris F, Pérez-Segura P, Gyorffy B, Pandiella A, Ocaña A. Díaz-Tejeiro C, et al. Int J Mol Sci. 2024 Nov 29;25(23):12875. doi: 10.3390/ijms252312875. Int J Mol Sci. 2024. PMID: 39684584 Free PMC article. Review.
Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.
Ge X, Zhang K, Zhu J, Chen Y, Wang Z, Wang P, Xu P, Yao J. Ge X, et al. Int J Biol Sci. 2025 Jan 1;21(1):63-74. doi: 10.7150/ijbs.101861. eCollection 2025. Int J Biol Sci. 2025. PMID: 39744438 Free PMC article. Review.

See all "Cited by" articles

References

1. Goulet, D. R. & Atkins, W. M. Considerations for the design of antibody-based therapeutics. J. Pharm. Sci. 109, 74–103 (2020). - PubMed - DOI
1. Sliwkowski, M. X. & Mellman, I. Antibody therapeutics in cancer. Science 341, 1192–1198 (2013). - PubMed - DOI
1. Pierpont, T. M., Limper, C. B. & Richards, K. L. Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Front. Oncol. 8, 163 (2018). - PubMed - PMC - DOI
1. Forecast, M.D. Global Cancer Monoclonal Antibodies Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Application, Type, Conjugate Cancer Therapies & Region – Industry Forecast (2021 to 2026), Vol. 2021 (Market Data Forecast, 2021).
1. Schroeder, H. W. Jr. & Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41–S52 (2010). - PubMed - PMC - DOI

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Goulet, D. R. & Atkins, W. M. Considerations for the design of antibody-based therapeutics. J. Pharm. Sci. 109, 74–103 (2020). - PubMed - DOI

[2] Goulet, D. R. & Atkins, W. M. Considerations for the design of antibody-based therapeutics. J. Pharm. Sci. 109, 74–103 (2020). - PubMed - DOI

[3] Sliwkowski, M. X. & Mellman, I. Antibody therapeutics in cancer. Science 341, 1192–1198 (2013). - PubMed - DOI

[4] Sliwkowski, M. X. & Mellman, I. Antibody therapeutics in cancer. Science 341, 1192–1198 (2013). - PubMed - DOI

[5] Pierpont, T. M., Limper, C. B. & Richards, K. L. Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Front. Oncol. 8, 163 (2018). - PubMed - PMC - DOI

[6] Pierpont, T. M., Limper, C. B. & Richards, K. L. Past, present, and future of rituximab—the world’s first oncology monoclonal antibody therapy. Front. Oncol. 8, 163 (2018). - PubMed - PMC - DOI

[7] Forecast, M.D. Global Cancer Monoclonal Antibodies Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Application, Type, Conjugate Cancer Therapies & Region – Industry Forecast (2021 to 2026), Vol. 2021 (Market Data Forecast, 2021).

[8] Forecast, M.D. Global Cancer Monoclonal Antibodies Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Application, Type, Conjugate Cancer Therapies & Region – Industry Forecast (2021 to 2026), Vol. 2021 (Market Data Forecast, 2021).

[9] Schroeder, H. W. Jr. & Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41–S52 (2010). - PubMed - PMC - DOI

[10] Schroeder, H. W. Jr. & Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41–S52 (2010). - PubMed - PMC - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advances in antibody-based therapy in oncology

Affiliations

Advances in antibody-based therapy in oncology

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical